Development of novel antitumor drugs targeting activated Ras by protein knockdown
Project/Area Number |
23890251
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
Drug development chemistry
|
Research Institution | National Institute of Health Sciences |
Principal Investigator |
HATTORI Takayuki 国立医薬品食品衛生研究所, 機能生化学部, 主任研究官 (50377751)
|
Project Period (FY) |
2011 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | Ras / 癌 / 分子標的治療 / タンパク質分解 |
Research Abstract |
In this study, we are developing the SNIPERs that specifically target activated mutant Ras proteins. We demonstrated that proliferation of tumor cells harboring activated mutant Ras was inhibited by ablation of mutant Ras. Furthermore, we identified some Ras-binding compounds as a ligand of SNIPER. We are now synthesizing bestatin-Ras-binding compounds hybrid (SNIPER).
|
Report
(3 results)
Research Products
(12 results)
-
-
-
-
-
-
-
-
-
[Presentation] Development of Hybrid Small Molecules That Induce IAP-Mediated Ubiquitylation and Proteasomal Degradation of Target Proteins in a Specific Manner2012
Author(s)
Mikihiko Naito, Keiichiro Okuhira, Yosuke Demizu, Yukihiro Itoh, Minoru Ishikawa, Nobumichi Ohoka, Norihito Shibata, Takayuki Hattori, Tomoko Nishimaki-Mogami, Masaaki Kurihara, and Yuichi Hashimoto
Organizer
Genetics and Chemistry Sharing a Language of Discovery
Place of Presentation
Boston, USA
Related Report
-
-
-